| 摘要 |
The invention relates to the use of a compound comprising the following amino acid sequence X<SUB>1</SUB>X<SUB>2</SUB>X<SUB>3</SUB>X<SUB>4</SUB>X<SUB>5</SUB>X<SUB>6</SUB>, wherein X<SUB>1 </SUB>is an amino acid, except of C, X<SUB>2 </SUB>is an amino acid, except of C, X<SUB>3 </SUB>is an amino acid, except of C, X<SUB>4 </SUB>is an amino acid, except of C, X<SUB>5 </SUB>is an amino acid, except of C, X<SUB>6 </SUB>is an amino acid, except of C, and wherein X<SUB>1</SUB>X<SUB>2</SUB>X<SUB>3</SUB>X<SUB>4</SUB>X<SUB>5</SUB>X<SUB>6 </SUB>is not DAEFRH, said compound having a binding capacity to an antibody being specific for the natural N-terminal Abeta42 sequence DAEFRH, and 5-mers thereof having a binding capacity to said antibody being specific for the natural N-terminal Abeta42 sequence DAEFRH, for the preparation of a vaccine for Alzheimer's disease. |
